NEW YORK (GenomeWeb) – The Ontario Institute for Cancer Research (OICR) has launched five translational research initiatives that will use genomics and other technologies to combat various cancers, Ontario’s Ministry of Research, Innovation, and Science announced today.
The programs will be supported with C$24 million ($17.9 million) over two years, and will specifically focus on acute leukemia, brain cancer, immuno-oncology, ovarian cancer, and pancreatic cancer.
The first initiative will be led by scientists from the University Health Network, who will use genomics, epigenomics, and bioinformatics to develop new biomarkers that can be used to predict how leukemia patients will respond to therapy, as well as the likelihood of disease recurrence.
The second program, led by researchers at the Hospital for Sick Kids, is investigating the cellular and genetic differences between medulloblastoma and glioblastoma multiforme in children and adults in order to better understand brain cancer and develop new treatments.
In the third initiative, researchers from University Health Network and the University of Ottawa will evaluate the therapeutic potential of an immunotherapeutic/cancer vaccine combination, and will conduct genomic and immune cell analyses in cancer patients undergoing immuno-oncology treatment, in order to gain insights into the mechanisms of response and drug resistance.